RT Journal Article
SR Electronic
T1 Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.03.22268599
DO 10.1101/2022.01.03.22268599
A1 Rajesh M Valanparambil
A1 Jennifer Carlisle
A1 Susanne L. Linderman
A1 Akil Akthar
A1 Ralph Linwood Millett
A1 Lilin Lai
A1 Andres Chang
A1 Ashley A. McCook
A1 Jeffrey Switchenko
A1 Tahseen H. Nasti
A1 Manpreet Saini
A1 Andreas Wieland
A1 Kelly E. Manning
A1 Madison Ellis
A1 Kathryn M. Moore
A1 Stephanie L. Foster
A1 Katharine Floyd
A1 Meredith E. Davis-Gardner
A1 Venkata-Viswanadh Edara
A1 Mit Patel
A1 Conor Steur
A1 Ajay K. Nooka
A1 Felicia Green
A1 Margaret A. Johns
A1 Fiona O’Brein
A1 Uma Shanmugasundaram
A1 Veronika I Zarnitsyna
A1 Hasan Ahmed
A1 Lindsay E. Nyhoff
A1 Grace Mantus
A1 Michael Garett
A1 Srilatha Edupuganti
A1 Madhusmita Behra
A1 Rustom Antia
A1 Jens Wrammert
A1 Mehul S. Suthar
A1 Madhav V. Dhodapkar
A1 Suresh Ramalingam
A1 Rafi Ahmed
YR 2022
UL http://medrxiv.org/content/early/2022/01/04/2022.01.03.22268599.abstract
AB Purpose We investigated SARS-CoV-2 mRNA vaccine-induced binding and live-virus neutralizing antibody response in NSCLC patients to the SARS-CoV-2 wild type strain and the emerging Delta and Omicron variants.Methods 82 NSCLC patients and 53 healthy adult volunteers who received SARS-CoV-2 mRNA vaccines were included in the study. Blood was collected longitudinally, and SARS-CoV-2-specific binding and live-virus neutralization response to 614D (WT), B.1.617.2 (Delta), B.1.351 (Beta) and B.1.1.529 (Omicron) variants were evaluated by Meso Scale Discovery (MSD) assay and Focus Reduction Neutralization Assay (FRNT) respectively. We determined the longevity and persistence of vaccine-induced antibody response in NSCLC patients. The effect of vaccine-type, age, gender, race and cancer therapy on the antibody response was evaluated.Results Binding antibody titer to the mRNA vaccines were lower in the NSCLC patients compared to the healthy volunteers (P=<0.0001). More importantly, NSCLC patients had reduced live-virus neutralizing activity compared to the healthy vaccinees (P=<0.0001). Spike and RBD-specific binding IgG titers peaked after a week following the second vaccine dose and declined after six months (P=<0.001). While patients >70 years had lower IgG titers (P=<0.01), patients receiving either PD-1 monotherapy, chemotherapy or a combination of both did not have a significant impact on the antibody response. Binding antibody titers to the Delta and Beta variants were lower compared to the WT strain (P=<0.0001). Importantly, we observed significantly lower FRNT50 titers to Delta (6-fold), and Omicron (79-fold) variants (P=<0.0001) in NSCLC patients.Conclusions Binding and live-virus neutralizing antibody titers to SARS-CoV-2 mRNA vaccines in NSCLC patients were lower than the healthy vaccinees, with significantly lower live-virus neutralization of B.1.617.2 (Delta), and more importantly, the B.1.1.529 (Omicron) variant compared to the wild-type strain. These data highlight the concern for cancer patients given the rapid spread of SARS-CoV-2 Omicron variant.Competing Interest StatementM.S.S serves on the advisory board for Moderna and Ocugen.Funding StatementResearch reported in this publication was supported in part by the National Cancer Institute of the National Institutes of Health under Award Number P50CA217691. Research reported in this publication was supported in part by the Biostatistics Shared Resource of Winship Cancer Institute of Emory University and NIH NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We acknowledge the support of Cancer Tissue and Pathology, Data and Technology Applications, and Biostatistics shared resource of the Winship Cancer Institute of Emory University and NIH NCI under award number P30CA138292.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Emory UniversityI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors